BOSCARO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.763
EU - Europa 1.437
AS - Asia 989
SA - Sud America 12
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 18.213
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.743
CN - Cina 657
FI - Finlandia 346
VN - Vietnam 288
SE - Svezia 257
DE - Germania 237
UA - Ucraina 205
IT - Italia 192
GB - Regno Unito 105
IE - Irlanda 32
IN - India 25
FR - Francia 23
NL - Olanda 17
CA - Canada 11
BZ - Belize 8
PE - Perù 7
HK - Hong Kong 6
RO - Romania 5
RU - Federazione Russa 5
TR - Turchia 5
BR - Brasile 4
EU - Europa 4
JP - Giappone 3
NZ - Nuova Zelanda 3
PH - Filippine 3
PL - Polonia 3
BE - Belgio 2
BG - Bulgaria 2
SD - Sudan 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
CH - Svizzera 1
CO - Colombia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ES - Italia 1
HR - Croazia 1
LU - Lussemburgo 1
MA - Marocco 1
NG - Nigeria 1
SI - Slovenia 1
Totale 18.213
Salva come PNG Salva come JPEG
Città #
Fairfield 2.595
Woodbridge 1.978
Ann Arbor 1.487
Houston 1.416
Chandler 1.116
Ashburn 1.037
Wilmington 962
Jacksonville 920
Cambridge 912
Seattle 854
Princeton 429
Dong Ket 288
San Diego 241
Roxbury 182
Beijing 165
Nanjing 140
Des Moines 135
Medford 130
Helsinki 118
Boardman 116
Padova 88
Guangzhou 61
Shenyang 50
Hebei 34
Dublin 32
Norwalk 32
Nanchang 31
Redwood City 30
Jiaxing 27
Changsha 25
Tianjin 24
Falls Church 16
New York 16
London 15
Ogden 15
Washington 15
Jinan 12
Kharkiv 12
Orange 10
San Jose 10
Borås 9
Columbus 9
Detroit 9
Kunming 9
Rome 9
Belize City 8
Dearborn 7
San Francisco 7
Tappahannock 7
Zhengzhou 7
Hangzhou 6
Kilburn 6
Lima 6
Haikou 5
Hefei 5
Indiana 5
Pune 5
Rockville 5
Southwark 5
Hong Kong 4
Milan 4
Nürnberg 4
Albuquerque 3
Chicago 3
Chiswick 3
Dallas 3
Foglianise 3
Hounslow 3
Hyderabad 3
Iasi 3
Kastamonu 3
Munich 3
Phoenix 3
Saint Louis 3
Samarate 3
Vicenza 3
Wandsworth 3
Anguillara Veneta 2
Ankara 2
Bologna 2
Bucharest 2
Buffalo 2
Chongqing 2
Florence 2
Frankfurt am Main 2
Groningen 2
Hanover 2
Henderson 2
Karasawa 2
Lappeenranta 2
Magdeburg 2
Menlo Park 2
Mestre 2
Mumbai 2
Naples 2
Ningbo 2
Paris 2
Redmond 2
Sassuolo 2
Sofia 2
Totale 16.008
Salva come PNG Salva come JPEG
Nome #
Age-related changes in glucocorticoid fast feedback inhibition of adrenocorticotropin in man 147
THE NATURAL HISTORY OF AUTOIMMUNE ADDISON'S DISEASE FROM THE DETECTION OF AUTOANTIBODIES TO DEVELOPMENT OF THE DISEASE: A LONG FOLLOW-UP STUDY ON 143 PATIENTS 145
A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC 141
Age and the metabolic syndrome affect salivary cortisol rhythm: Data from a community sample 132
Adrenocortical carcinoma: Experience in 45 patients 129
Effect of ketanserin in primary aldosteronism. 127
SELECTIVE VENOUS SAMPLING IN THE DIFFERENTIAL-DIAGNOSIS OF ACTH-DEPENDENT CUSHINGS-SYNDROME 125
First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS 124
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome 123
Effect of surgical treatment on hypertension in Cushing's syndrome 123
Effect of metoclopramide on plasma aldosterone in normal subjects, primary aldosteronism and hypopituitarism. 121
An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: A single-centre experience 120
Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors 119
Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. 119
Effects of Taxol on the human NCI-H295 adrenocortical carcinoma cell line. 118
New insight into the Hypercoagulability of Cushing's Syndrome 117
Screening tests for cushing's syndrome: Urinary free cortisol role measured by LC-MS/MS 116
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. 115
25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese 112
Adrenocortical scintigraphic characterization of incidentally discovered adrenal massess 111
Aldosterone, calcium, and hypertension. 111
Systematic review of surgical treatment of subclinical Cushing's syndrome 110
Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. 109
Improved salivary cortisol rhythm with dual-release hydrocortisone 109
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells 109
The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence" 109
Metyrapone treatment in Cushing’s syndrome: a real-life study 108
24-HOUR BLOOD-PRESSURE PROFILE IN ADDISONS-DISEASE 107
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 107
Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer 106
Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism 106
Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI 106
LIFE EVENTS IN THE PATHOGENESIS OF GRAVES-DISEASE - A CONTROLLED-STUDY 105
Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and Herpes Simplex Virus thymidine kinase 105
Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. 104
In situ analysis of human menin in normal and neoplastic pancreatic tissues: Evidence for differential expression in exocrine and endocrine cells 104
PATTERNS OF ACTH RESPONSE TO OCRH IN CUSHINGS-DISEASE - CORRELATION WITH HISTOLOGICAL/IMMUNOCYTOCHEMICAL FINDINGS 103
Effect of digoxin on the in vitro secretion of renin and angiotensin II/III immunoreactivity by the human adrenal gland 103
Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study 102
Plasma renin activity and urinary aldosterone in acromegaly. 101
Development of overt Cushing's syndrome in patients with adrenal incidentaloma 101
Comment - Is there a role for low doses of mitotane (o,p '-DDD) as adjuvant therapy in adrenocortical carcinoma? 101
The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice 100
Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency 100
Prevalence and natural history of adrenal incidentalomas. 100
EFFECTS OF INHALED BECLOMETHASONE ON AIRWAY RESPONSIVENESS IN OCCUPATIONAL ASTHMA - PLACEBO-CONTROLLED STUDY OF SUBJECTS SENSITIZED TO TOLUENE DIISOCYANATE 99
Risk factors and long-term outcome in pituitary-dependent Cushing's disease 99
Association of primary aldosteronism with chronic thyroiditis 99
In vitro evidence for local generation of renin and angiotensin II/III immunoreactivity by the human adrenal gland 98
Persistent psychological distress in patients treated for endocrine disease 98
Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study 98
Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse 97
A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype 97
Second-line tests in the differential diagnosis of ACTH-dependent Cushing’s syndrome 97
Diagnosis and management of adrenal incidentalomas 94
Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors. 93
Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies. 92
Investigation of N-cadherin/β-catenin expression in adrenocortical tumors 92
ANXIETY SENSITIVITY IN ESSENTIAL-HYPERTENSION 92
DEFECTS OF STEROIDOGENESIS. 91
Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas 91
Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome 91
Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. 91
Effect of serotonin on plasma aldosterone in man. 91
Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. 91
The prevalence of HTLV-III and HTLV-I antibodies in serum of hemophiliacs. 91
The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line 91
Endocrine aspects of cancer gene therapy 91
Adrenal incidentalomas. A proposal for an evaluation score. 91
Psychosocial impairment in patients treated for pituitary disease: a controlled study 90
Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. 90
Effect of naloxone on the adrenal cortex in primary aldosteronism. 90
Gene therapy for thyroid cancer 89
Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome 89
Opioid modulation of normal and pathological human chromaffin tissue. 89
New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography 89
LA PHLEBOGRAPHIE SURRENALIENNE DANS L'HYPERALDOSTERONISME PRIMAIRE. 88
New perspectives for gene therapy in endocrinology 88
A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma 88
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 88
DISSEMINATED NOCARDIOSIS IN A PATIENT WITH CUSHINGS-SYNDROME 87
Managing Cushing's disease: the state of the art. 87
Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. 87
LOW-DOSE KETOCONAZOLE TREATMENT IN HIRSUTE WOMEN 87
POTENTIAL THERAPEUTIC EFFECTS OF RITANSERIN IN CUSHINGS-DISEASE 86
Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications 86
Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role 86
Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor 86
A clinical index for rating severity in Cushing's syndrome 85
Role of bilateral adrenalectomy in Cushing's disease 85
Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. 85
Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing's syndrome 84
Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma 84
Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH dependent Cushing's syndrome 84
Steroids and Hypertension 84
Risk factors and long-term follow-up of adrenal incidentalomas 83
Life events in the pathogenesis of hyperprolactinemia 82
Prolonged treatment of Cushing's disease by ketoconazole 82
Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism 82
Plasma renin activity and urinary aldosterone in Cushing's syndrome. 82
Totale 10.037
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.713
article - articoli 53.088
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 812
Totale 108.613
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.701 0 0 0 0 0 0 0 0 0 369 735 597
2019/20204.174 598 124 71 518 432 344 391 463 439 359 227 208
2020/20212.643 125 212 84 230 102 250 97 247 391 198 276 431
2021/20223.196 67 395 388 253 135 193 171 355 132 70 346 691
2022/20232.335 560 227 32 280 382 318 13 142 256 9 84 32
2023/2024620 44 123 112 56 75 76 55 46 21 12 0 0
Totale 18.392